Table 2.

Potential biomarker EV ncRNAs in gynecological malignancies.

Cancer type	Source	ncRNAs	Biomarker	qPCR verification	Reference
CC	Plasma	Let-7d-3p miR-30d-5p	Diagnosis	YES	Zheng et al. [80]
CC	Plasma	miR-125a-5p	Diagnosis	YES	Lv et al. [122]
CC	Serum	lncRNA-EXOC7	Diagnosis, treatment effect and recurrence	YES	Guo et al. [81]
OC	Serum	miR-484	Prognosis	YES	Zhang et al. [88]
OC	Serum	miR-145, miR-200c	Diagnosis	YES	Kim et al. [123]
OC	Serum	aHIF	Prognosis	YES	Tang et al. [89]
OC	Serum	miR-1307 miR-375	Diagnosis	YES	Su et al. [90]
OC	Serum	MALAT1	Prognosis	YES	Qiu et al. [60]
OC	Serum	miR-373, miR-200a, miR-200b, miR-200c	Diagnosis, prognosis	YES	Meng et al. [124]
OC	Serum	miR-34a	Prognosis	YES	Maeda et al. [91]
OC	Serum	miR-1290	Prognosis	YES	Kobayashi et al. [125]
OC	Plasma	miR‑93‑5p miR-122-5p miR‑99b‑5p	N.D	YES	Zhang et al. [126]
OC	Plasma	miR-23a, miR-92a miR-21, miR-100, miR-200b miR-16	Diagnosis, prognosis	No	Pan et al. [92]
OC	Ascites	miR-149-3p, miR-222-5p	Prognosis	YES	Li et al. [93]
OC	OC cells	let-7, miR-200 miRNA family	Invasiveness	YES	Kobayashi et al. [127]
EC	Peritoneal lavage	miR-383-5p, miR-10b-5p, miR-34c-3p, miR-449b-5p, miR-34c-5p, miR-200b-3p, miR-2110, and miR-34b-3p	N.D	NO	Roman-Canal et al. [107]
EC	Serum	209 upregulated and 66 downregulated circRNAs	N.D	Confirmed (hsa circ 0109046 and hsa circ 0002577)	Xu et al. [105]
EC	Urine	miR-200c-3p	N.D	YES	Srivastava et al. 2018 [106]

N.D not determined.